Cargando…
Clinical response to benralizumab can be predicted by combining clinical outcomes at 3 months with baseline characteristics
BACKGROUND: Benralizumab is highly effective in many, but not all, patients with severe asthma. Baseline characteristics alone are insufficient to predict an individual's probability of long-term benralizumab response. The objectives of the present study were to: 1) study whether parameters at...
Autores principales: | Kroes, Johannes A., de Jong, Kim, Hashimoto, Simone, Zielhuis, Sander W., van Roon, Eric N., Sont, Jacob K., ten Brinke, Anneke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086738/ https://www.ncbi.nlm.nih.gov/pubmed/37057095 http://dx.doi.org/10.1183/23120541.00559-2022 |
Ejemplares similares
-
Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report
por: Kroes, Johannes Anthon, et al.
Publicado: (2022) -
Cumulative corticosteroid-sparing effect of anti-interleukin-5/5Ra in eosinophilic asthma
por: Kroes, Johannes A., et al.
Publicado: (2022) -
Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma
por: Bleecker, Eugene R., et al.
Publicado: (2018) -
Real-life experience with benralizumab during 6 months
por: Padilla-Galo, A., et al.
Publicado: (2020) -
The clinical profile of benralizumab in the management of severe
eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)